<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526656</url>
  </required_header>
  <id_info>
    <org_study_id>CASE24806</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>GA6180CV</secondary_id>
    <nct_id>NCT00526656</nct_id>
  </id_info>
  <brief_title>Sunitinib in Treating Patients With Locally Advanced Bladder Cancer</brief_title>
  <official_title>Phase II Single Arm, Open Label, Single Institution Study of Neoadjuvant Sunitinib (SUTENT) in Patients With Muscle-Invasive Locally Advanced Transitional Cell Carcinoma of the Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before&#xD;
      surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be&#xD;
      removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well sunitinib works in&#xD;
      treating patients with locally advanced bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the pathologic complete response rate of sunitinib malate in patients with&#xD;
           muscle-invasive locally advanced transitional cell carcinoma (TCC) of the bladder.&#xD;
&#xD;
        -  To evaluate the safety and tolerability of sunitinib malate administered prior to&#xD;
           radical cystectomy, including surgical outcome and surgical complications.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the clinical effects of sunitinib malate administered prior to radical&#xD;
           cystectomy and bilateral lymph node dissection, including overall response rate using&#xD;
           RECIST defined criteria, cytology, and histologic appearance of surgical specimen as&#xD;
           well as time to progression.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  To assess pre-treatment tissue baseline angiogenic markers and to evaluate the magnitude&#xD;
           of the difference among these variables with post-treatment tumor tissue after&#xD;
           neoadjuvant sunitinib malate.&#xD;
&#xD;
        -  To evaluate the effects of sunitinib malate on immunosuppressive regulatory T cells.&#xD;
&#xD;
      OUTLINE: Patients receive oral sunitinib malate once daily in weeks 1-4 (1 course). Patients&#xD;
      undergo restaging within 1 week prior to surgery and then undergo radical cystectomy and&#xD;
      bilateral lymph node dissection on day 42. Patients achieving a complete pathologic response&#xD;
      at the time of surgery may receive 6 more courses of adjuvant sunitinib malate beginning 28&#xD;
      days after surgery at the discretion of the treating physician. Patients found to have&#xD;
      high-risk features (i.e. pT3 or greater tumor and evidence of disease in any of the lymph&#xD;
      nodes resected) are offered standard adjuvant systemic chemotherapy at the discretion of the&#xD;
      treating physician.&#xD;
&#xD;
      Tumor tissue from pretreatment biopsy and radical cystectomy will be tested for VEGFR-1,&#xD;
      VEGFR-2 and PDGF-R expression by IHC. Samples are also analyzed for quantification of cell&#xD;
      proliferation and apoptosis and immunosuppressive regulatory T cells (T-reg) and T-reg&#xD;
      functions.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 28 days after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate of Sunitinib</measure>
    <time_frame>at 6 weeks</time_frame>
    <description>Number of participants who at the time of cystectomy, to have no evidence of tumor grossly and microscopically on routine Hematoxylin and Eosin stain (H&amp;E) (pathologic complete response or P0) will be defined as responders. All cases will be defined as responders (P0) or non-responders based on the presence of residual tumor.&#xD;
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.&#xD;
Progression (PD): At least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.&#xD;
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since the treatment started.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Treatment to Surgical Complication and Morbidity</measure>
    <time_frame>following surgery at 6 weeks</time_frame>
    <description>Determine if surgical morbidity was increased from time of last dose to time of surgery is defined as the number of subjects with increase non-ileus related morbidity due to treatment drug during the 2 week rest period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>at 4 weeks post-surgery</time_frame>
    <description>Time to progression will be measured as the time from when the patient started treatment to the time the patient is first recorded as having disease progression or the date of death if the patient dies due to causes other than disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>sunitinib malate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>50mg PO daily 4 weeks on -2 weeks off</description>
    <arm_group_label>sunitinib malate</arm_group_label>
    <other_name>Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histological confirmed transitional cell carcinoma (TCC) of the bladder&#xD;
&#xD;
               -  Patients with mixed tumors (i.e., tumors containing elements of squamous cell or&#xD;
                  adenocarcinoma) are eligible&#xD;
&#xD;
               -  Patients with pure non-transitional cell carcinomas are not eligible&#xD;
&#xD;
          -  Meets 1 of the following staging criteria:&#xD;
&#xD;
               -  Tumors ≥ cT2&#xD;
&#xD;
                    -  Patients with cT2 lesions must have either a bulky or fixed lesion at the&#xD;
                       time of physical examination and/or scans&#xD;
&#xD;
               -  Any cT stage with nodal-positive disease (documented by scans)&#xD;
&#xD;
                    -  Patients with (+) N1-N3 disease are eligible&#xD;
&#xD;
          -  Candidate for radical cystectomy in ≥ 8 weeks while neoadjuvant sunitinib malate is&#xD;
             administered&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any evidence of distant metastasis (excluding pelvic or retroperitoneal lymph nodes)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-1 (Karnofsky PS greater than 70%)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mcL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mcL&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 3.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (≤ 10 times ULN in presence of bone metastasis)&#xD;
&#xD;
          -  Serum calcium ≤ 12 mg/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  INR ≤ 1.5 (except for patients receiving warfarin therapy)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Disease-free of prior malignancies for ≥ 5 years except for currently treated basal&#xD;
             cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  NCI CTCAE grade 3 hemorrhage within 4 weeks of starting study treatment&#xD;
&#xD;
          -  Any of the following within 6 months prior to study drug administration:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Severe/unstable angina&#xD;
&#xD;
               -  Coronary/peripheral artery bypass graft&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Cerebrovascular accident or transient ischemic attack&#xD;
&#xD;
               -  Pulmonary embolism&#xD;
&#xD;
          -  Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2, atrial fibrillation of any grade,&#xD;
             or prolongation of the QTc interval to &gt; 450 msec for males or &gt; 470 msec for females&#xD;
&#xD;
          -  Hypertension that cannot be controlled by medications&#xD;
&#xD;
          -  Known HIV or AIDS-related illness&#xD;
&#xD;
          -  Infectious hepatitis type A, B, or C&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition, or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or study&#xD;
             drug administration or may interfere with the interpretation of study results&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Other systemic chemotherapy must have been completed at least 5 years prior to&#xD;
             enrollment&#xD;
&#xD;
          -  No prior systemic chemotherapy for bladder cancer&#xD;
&#xD;
          -  No other approved or investigational anticancer treatment will be permitted during the&#xD;
             study period, including chemotherapy, biological response modifiers, hormone therapy,&#xD;
             surgery, palliative radiotherapy, or immunotherapy&#xD;
&#xD;
          -  No other investigational drug may be used during treatment on this protocol&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior intravesical chemotherapy or immunotherapy&#xD;
&#xD;
          -  Prior treatment with any other antiangiogenic therapy (including immunomodulatory&#xD;
             agents such as thalidomide and lenalidomide and anti-VEGF therapy with agents such as&#xD;
             bevacizumab, sunitinib malate, and sorafenib tosylate)&#xD;
&#xD;
          -  Prior surgery, radiotherapy, or systemic therapy within 4 weeks of starting the study&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge A. Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 5, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <results_first_submitted>February 20, 2019</results_first_submitted>
  <results_first_submitted_qc>March 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eleven patients were entered into the trial between 9/07 and 12/09 from medical clinic. Two patients were considered ineligible and received no treatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sunitinib Malate</title>
          <description>Drug&#xD;
sunitinib malate : 50mg PO daily 4 weeks on -2 weeks off</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants that were on study.</population>
      <group_list>
        <group group_id="B1">
          <title>Sunitinib Malate</title>
          <description>Drug&#xD;
sunitinib malate : 50mg PO daily 4 weeks on -2 weeks off</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="51" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate of Sunitinib</title>
        <description>Number of participants who at the time of cystectomy, to have no evidence of tumor grossly and microscopically on routine Hematoxylin and Eosin stain (H&amp;E) (pathologic complete response or P0) will be defined as responders. All cases will be defined as responders (P0) or non-responders based on the presence of residual tumor.&#xD;
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.&#xD;
Progression (PD): At least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.&#xD;
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since the treatment started.</description>
        <time_frame>at 6 weeks</time_frame>
        <population>Participants who completed treatment and surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Malate</title>
            <description>Drug&#xD;
sunitinib malate: 50mg PO daily 4 weeks on -2 weeks off</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate of Sunitinib</title>
          <description>Number of participants who at the time of cystectomy, to have no evidence of tumor grossly and microscopically on routine Hematoxylin and Eosin stain (H&amp;E) (pathologic complete response or P0) will be defined as responders. All cases will be defined as responders (P0) or non-responders based on the presence of residual tumor.&#xD;
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.&#xD;
Progression (PD): At least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.&#xD;
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since the treatment started.</description>
          <population>Participants who completed treatment and surgery</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Treatment to Surgical Complication and Morbidity</title>
        <description>Determine if surgical morbidity was increased from time of last dose to time of surgery is defined as the number of subjects with increase non-ileus related morbidity due to treatment drug during the 2 week rest period.</description>
        <time_frame>following surgery at 6 weeks</time_frame>
        <population>Participants who received treatment and surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Malate</title>
            <description>Drug&#xD;
sunitinib malate : 50mg PO daily 4 weeks on -2 weeks off</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Treatment to Surgical Complication and Morbidity</title>
          <description>Determine if surgical morbidity was increased from time of last dose to time of surgery is defined as the number of subjects with increase non-ileus related morbidity due to treatment drug during the 2 week rest period.</description>
          <population>Participants who received treatment and surgery.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time to progression will be measured as the time from when the patient started treatment to the time the patient is first recorded as having disease progression or the date of death if the patient dies due to causes other than disease progression.</description>
        <time_frame>at 4 weeks post-surgery</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib Malate</title>
            <description>Drug&#xD;
sunitinib malate : 50mg PO daily 4 weeks on -2 weeks off</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time to progression will be measured as the time from when the patient started treatment to the time the patient is first recorded as having disease progression or the date of death if the patient dies due to causes other than disease progression.</description>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (SAEs and AEs) collected from consent signed, while on treatment and followed 28 days after the last dose of treatment or until resolved or determined chronic or stable, whichever is later.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sunitinib Malate</title>
          <description>Drug&#xD;
sunitinib malate : 50mg PO daily 4 weeks on -2 weeks off</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term - Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with no more than Grade 2 ANC: Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU - Urethra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis, middle ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Salivary gland changes/saliva</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia (fever of unknown origin &gt;=38.5; no infection, ANC&lt;1.0x10e9/L)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU - Bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Urethra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urine color change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menses (change from baseline)</sub_title>
                <description>change from baseline</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Wound complication, non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Scalp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Garcia, MD</name_or_title>
      <organization>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</organization>
      <phone>216-444-7774</phone>
      <email>garciaj4@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

